TC Biopharm Delays Yearly Report Filing

TC Biopharm (Holdings) ( (TCBPY) ) has released a notification of late filing.

TC Biopharm (Holdings) PLC has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the time constraints associated with compiling, disseminating, and reviewing the required information, which would have caused undue hardship and expense. The company expects to file the report within 15 days following the original due date. There are no anticipated significant changes in the financial results compared to the previous fiscal year. The notification was signed by Martin Thorp, the Chief Financial Officer, who assured that the company is committed to maintaining compliance.

Spark’s Take on TCBPY Stock

According to Spark, TipRanks’ AI Analyst, TCBPY is a Underperform.

TC Biopharm’s overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock’s financial instability and operational inefficiencies are major concerns.

To see Spark’s full report on TCBPY stock, click here.

More about TC Biopharm (Holdings)

YTD Price Performance: -96.93%

Average Trading Volume: 357,301

Technical Sentiment Signal: Buy

Current Market Cap: $7,850

See more insights into TCBPY stock on TipRanks’ Stock Analysis page.